LGND
HealthcareLigand Pharmaceuticals Incorporated · Biotechnology · $4B
LGND — Key Takeaways
✅ Strengths
LGND — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | 56.6 | 46.9 | 41.0 | 77.4 | 77.7 | 49.8 | 0.0 |
| Apr 7, 2026 | 56.6 | 46.9 | 41.0 | 77.4 | 77.7 | 49.8 | 0.0 |
| Apr 6, 2026 | 56.6 | 46.9 | 41.0 | 77.4 | 77.7 | 49.8 | 0.0 |
| Apr 5, 2026 | 56.6 | 46.9 | 41.0 | 77.4 | 77.7 | 49.8 | 0.0 |
| Apr 4, 2026 | 56.6 | 46.9 | 41.0 | 77.4 | 77.7 | 49.8 | 0.0 |
| Apr 3, 2026 | 56.6 | 46.9 | 41.0 | 77.4 | 77.7 | 49.8 | 0.0 |
| Apr 2, 2026 | 56.6 | 46.9 | 41.0 | 77.4 | 77.7 | 49.8 | — |
LGND — Pillar Breakdown
Quality
— 46.9/100 (25%)Ligand Pharmaceuticals Incorporated has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 77.4/100 (20%)Ligand Pharmaceuticals Incorporated is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 77.7/100 (15%)Ligand Pharmaceuticals Incorporated carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 49.8/100 (15%)Ligand Pharmaceuticals Incorporated has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 41/100 (30%)Ligand Pharmaceuticals Incorporated possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LGND.
Score Composition
More Stock Analysis
How is the LGND UQS Score Calculated?
The UQS (Unified Quality Score) for Ligand Pharmaceuticals Incorporated is calculated using a proprietary 5-pillar framework with 25 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Ligand Pharmaceuticals Incorporated's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Ligand Pharmaceuticals Incorporated is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.